← All trials
NCT04476719
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 9, 2020
- Primary completion
- Jul 22, 2020
- Completion date
- Aug 20, 2020
- First posted
- Jul 20, 2020
- Last posted
- Jul 20, 2020
- Enrollment
- 18
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.Lead sponsor
- Farmagen Ar-Ge Biyot. Ltd. StiCollaborator
- Farmagen Ar-Ge Biyot. Ltd. StiStudy director
- Farmagen Ar-Ge Biyot. Ltd. StiOverall official - principal investigator
- Novagenix Bioanalytical Drug R&D CenterCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.